Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| liposomal doxorubicin treatment | intravenous liposomal doxorubicin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| liposomal doxorubicin | Drug | intravenous liposomal doxorubicin |
|
| Measure | Description | Time Frame |
|---|---|---|
| the incidence of interstitial pneumonia | interstitial pneumonia is defined as positive CT scan with or without positive respiratory symptoms | up to one month after completion of study treatment |
| Measure | Description | Time Frame |
|---|---|---|
| overall response rate | percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria | 21 days after completion of study treatment |
| adverse events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
de novo lymphoma patients
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| WL Z | Contact | 64370045 | 610707 | zhao.weili@yahoo.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ruijin Hospital | Recruiting | Shanghai | Shanghai Municipality | 200025 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C506643 | liposomal doxorubicin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
number of participants with treatment-related adverse events mainly include liposomal related AEs, eg cardiotoxicity and the incidence of hand-foot syndrome
| up to 30 days after completion of study treatment |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |